Echo Therapeutics, Inc. (ECTE.OB) Announces Clinical Study for New Glucose Monitoring Product
Echo Therapeutics, Inc., a diabetes management company developing a new needle-free Glocose Monitoring System, reports starting a new a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring product. The (tCGM System) study includes patients with Type 1 and Type 2 diabetes. The purpose of the study is to test the performance of its new one-piece, cost-effective biosensor. Echo expects to announce completed results of the study by the fourth quarter of 2009. Echo's pilot clinical study will enroll patients that have either type 1 or type 2 diabetes and will compare data obtained from its Symphony tCGM System with…